
    
      This is a randomized, double-blind, placebo-controlled, single ascending IV dose study
      conducted at one study center in the United States (US). One (1) cohort of 12 subjects (6
      active and 6 placebo) and two (2) cohorts of 8 subjects (6 active and 2 placebo) are planned
      for evaluation. Subjects will participate in only one cohort. Safety will be assessed
      throughout the study and serial blood samples and urine samples will be collected for the
      safety and PK assessment of GMI-1271.
    
  